• OUR COMPANY
    • LEADERSHIP
    • BOARD OF DIRECTORS
  • OUR SCIENCE
    • COMBINATION DRUGS
    • PROCEDURAL SEDATION AND ANALGESIA
  • OUR FOCUS
    • MARKET EXPANSION
  • NEWS
Melt PharmaceuticalsMelt Pharmaceuticals
Menu
  • OUR COMPANY
    • LEADERSHIP
    • BOARD OF DIRECTORS
  • OUR SCIENCE
    • COMBINATION DRUGS
    • PROCEDURAL SEDATION AND ANALGESIA
  • OUR FOCUS
    • MARKET EXPANSION
  • NEWS

NEWS

PRESS RELEASES

MAY 4, 2022

MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study

PRESS RELEASE

MARCH 10, 2022

Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer

PRESS RELEASE

JANUARY 4, 2022

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

PRESS RELEASE

SEPTEMBER 2, 2021

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

PRESS RELEASE

FEBRUARY 9, 2021

Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate

PRESS RELEASE

JULY 30, 2020

Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development

PRESS RELEASE

FEBRUARY 13, 2019

Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

PRESS RELEASE

FEBRUARY 5, 2019

Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary

PRESS RELEASE

MARCH 27, 2018

Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

PRESS RELEASE

RELATED NEWS

CMS proposes Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System changes for 2019 (CMS-1695-P)

MORE

QUICK LINKS

  • our company
  • our science
  • our focus
  • news

CONTACT US

Melt Pharmaceuticals
6 Cadillac Drive
Suite 320
Brentwood, TN 37027
phone: 615-733-4730
info@meltpharma.com

INVESTORS & MEDIA

info@meltpharma.com

Privacy Policy
Terms of Use